文献速递呼吸危重症与机械通气

过敏性休克:机制、诊断与治疗

Anaphylaxis.
PubMed 文献 · Chest · 2017-08-08

过敏性休克是由肥大细胞和嗜碱性粒细胞释放介质引发的全身性致命性疾病,累及皮肤、肺、胃肠和心血管系统,可致气道梗阻和心肺骤停。诊断依据临床,血浆类胰蛋白酶和尿组胺常升高但不应延迟治疗。治疗核心是避免触发因素并及时使用肾上腺素,辅助治疗包括液体、支气管扩张剂、抗组胺药和糖皮质激素。

要点

  • 过敏性休克是临床诊断,疑似即应使用肾上腺素,不得延迟。
  • 血浆类胰蛋白酶和尿组胺可辅助确诊,但不应等待结果再治疗。
  • 辅助治疗包括液体、支气管扩张剂、抗组胺药和糖皮质激素。

核心结论

  • 过敏性休克是经IgE介导或非IgE介导机制触发的全身性致命性疾病,诊断基于临床,肾上腺素为一线治疗且不应延迟。

主要发现

  • 过敏性休克和血管性水肿可导致致命性气道梗阻和心肺骤停,引起低氧血症和/或休克。
  • 报告提示过敏性休克的诊断不足和治疗不足很常见。
  • 近期描述了鸟蛋综合征、猪猫综合征、哺乳动物肉延迟过敏和多种肥大细胞活化障碍等新综合征。
  • 体位性心动过速综合征、类癌综合征、Munchausen喘鸣和做作性过敏性休克可表现相似,需纳入鉴别诊断。
  • 血浆类胰蛋白酶和尿组胺水平常升高,可辅助诊断确认,但检测不应延迟治疗。

临床怎么用

  • 疑似过敏性休克时不应延迟使用肾上腺素,并避免已知触发因素。
  • 辅助治疗包括液体、支气管扩张剂、抗组胺药和糖皮质激素。
  • 心肺骤停或气道/血管受累者需机械通气、血管升压药和ICU高级生命支持。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anaphylaxis is a systemic, life-threatening disorder triggered by mediators released by mast cells and basophils activated via allergic (IgE-mediated) or nonallergic (non-IgE-mediated) mechanisms. It is a rapidly evolving, multisystem process involving the integumentary, pulmonary, gastrointestinal, and cardiovascular systems. Anaphylaxis and angioedema are serious disorders that can lead to fatal airway obstruction and culminate in cardiorespiratory arrest, resulting in hypoxemia and/or shock. Often, these disorders can be appropriately managed in an outpatient setting; however, these conditions can be severe enough to warrant evaluation of the patient in the ED and in some cases, hospitalization, and management in an ICU. Reports suggest that underdiagnosis and undertreatment of anaphylaxis are common. Several new syndromes have been described recently including bird-egg, pork-cat, delayed allergy to mammalian meat and a diverse group of mast cell activation disorders. Conditions such as postural orthostatic tachycardia syndrome, carcinoid syndrome, Munchausen stridor, and factitious anaphylaxis can present similarly and need to be included in the differential diagnosis. Anaphylaxis is a clinical diagnosis, but plasma tryptase and urinary histamine levels are often elevated, allowing diagnostic confirmation; however, diagnostic testing should not delay treatment as results may not be immediately available. The sine qua non of treatment is avoidance of any known triggers and epinephrine, which should never be delayed if this disorder is suspected. Secondary treatments include fluids, bronchodilators, antihistamines, and glucocorticoids. Patients with cardiopulmonary arrest or airway or vascular compromise require mechanical ventilation, vasopressors, and other advanced life support in the ICU.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. LoVerde D, Iweala OI, Eginli A, et al. Anaphylaxis. Chest. 2017. PMID: 28800865. doi:10.1016/j.chest.2017.07.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。